Clinical trial
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in…
NCT00379795 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00379795 |
|---|---|
| Title | An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO |
| Official title | An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a… |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization, Age-related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Ranibizumab 0.5 mg |
| Enrollment | 853 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 22, 2006 |
| Last update posted | May 11, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: